Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Background and AimPatients with non‐alcoholic fatty liver disease (NAFLD) exhibit compositional changes in their gut microbiome, which represents a potential therapeutic target. Probiotics, prebiotics, and synbiotics are microbiome‐targeted therapies that have been proposed as treatment for NAFLD. We aim to systematically review the effects of these therapies in liver‐related outcomes of NAFLD patients.MethodsWe conducted a systematic search in Embase (Ovid), Medline (Ovid), Scopus, Cochrane, and EBSCOhost from inception to August 19, 2022. We included randomized controlled trials (RCTs) that treated NAFLD patients with prebiotics and/or probiotics. We meta‐analyzed the outcomes using standardized mean difference (SMD) and assessed study heterogeneity using Cochran's Q test and I2 statistics. Risk of bias was assessed using the Cochrane Risk‐of‐Bias 2 tool.ResultsA total of 41 (18 probiotics, 17 synbiotics, and 6 prebiotics) RCTs were included. Pooled data demonstrated that the intervention had significantly improved liver steatosis (measured by ultrasound grading) (SMD: 4.87; 95% confidence interval [CI]: 3.27, 7.25), fibrosis (SMD: −0.61 kPa; 95% CI: −1.12, −0.09 kPa), and liver enzymes including alanine transaminase (SMD: −0.86 U/L; 95% CI: −1.16, −0.56 U/L), aspartate transaminase (SMD: −0.87 U/L; 95% CI: −1.22, −0.52 U/L), and gamma‐glutamyl transferase (SMD: −0.77 U/L; 95% CI: −1.26, −0.29 U/L).ConclusionsMicrobiome‐targeted therapies were associated with significant improvements in liver‐related outcomes in NAFLD patients. Nevertheless, limitations in existing literature like heterogeneity in probiotic strains, dosage, and formulation undermine our findings. This study was registered with PROSPERO (CRD42022354562) and supported by the Nanyang Technological University Start‐up Grant and Wang Lee Wah Memorial Fund.
Background and AimPatients with non‐alcoholic fatty liver disease (NAFLD) exhibit compositional changes in their gut microbiome, which represents a potential therapeutic target. Probiotics, prebiotics, and synbiotics are microbiome‐targeted therapies that have been proposed as treatment for NAFLD. We aim to systematically review the effects of these therapies in liver‐related outcomes of NAFLD patients.MethodsWe conducted a systematic search in Embase (Ovid), Medline (Ovid), Scopus, Cochrane, and EBSCOhost from inception to August 19, 2022. We included randomized controlled trials (RCTs) that treated NAFLD patients with prebiotics and/or probiotics. We meta‐analyzed the outcomes using standardized mean difference (SMD) and assessed study heterogeneity using Cochran's Q test and I2 statistics. Risk of bias was assessed using the Cochrane Risk‐of‐Bias 2 tool.ResultsA total of 41 (18 probiotics, 17 synbiotics, and 6 prebiotics) RCTs were included. Pooled data demonstrated that the intervention had significantly improved liver steatosis (measured by ultrasound grading) (SMD: 4.87; 95% confidence interval [CI]: 3.27, 7.25), fibrosis (SMD: −0.61 kPa; 95% CI: −1.12, −0.09 kPa), and liver enzymes including alanine transaminase (SMD: −0.86 U/L; 95% CI: −1.16, −0.56 U/L), aspartate transaminase (SMD: −0.87 U/L; 95% CI: −1.22, −0.52 U/L), and gamma‐glutamyl transferase (SMD: −0.77 U/L; 95% CI: −1.26, −0.29 U/L).ConclusionsMicrobiome‐targeted therapies were associated with significant improvements in liver‐related outcomes in NAFLD patients. Nevertheless, limitations in existing literature like heterogeneity in probiotic strains, dosage, and formulation undermine our findings. This study was registered with PROSPERO (CRD42022354562) and supported by the Nanyang Technological University Start‐up Grant and Wang Lee Wah Memorial Fund.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.